Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111605BIZWIRE_USPR_____20260311_BW456427) on March 11, 2026, and is solely responsible for the information contained therein.